Holen Sie sich die Stockscreener-App
0.6251
2.64%
0.0161
Handel nachbörslich:
.63
0.0049
+0.78%
Schlusskurs vom Vortag:
$0.609
Offen:
$0.617173
24-Stunden-Volumen:
9,961
Relative Volume:
0.21
Marktkapitalisierung:
$3.48M
Einnahmen:
$14.64M
Nettoeinkommen (Verlust:
$-13.74M
KGV:
-0.086
EPS:
-7.27
Netto-Cashflow:
$-5.04M
1W Leistung:
+8.98%
1M Leistung:
+12.83%
6M Leistung:
+0.02%
1J Leistung:
-71.19%
1-Tages-Spanne:
$0.6123
$0.6259
1-Wochen-Bereich:
$0.5755
$0.6259
52-Wochen-Spanne:
$0.3611
$2.4521
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Firmenname
Novabay Pharmaceuticals Inc
Sektor
Branche
Telefon
510-899-8800
Adresse
2000 Powell Street, Suite 1150, Emeryville, CA
Vergleichen Sie NBY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
0.6251 | 3.48M | 14.64M | -13.74M | -5.04M | -7.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-09-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-07-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-15 | Bestätigt | Laidlaw | Buy |
| 2017-06-05 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-27 | Eingeleitet | Laidlaw | Buy |
| 2017-02-06 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-03-07 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-12-14 | Bestätigt | Maxim Group | Buy |
| 2015-04-30 | Fortgesetzt | Maxim Group | Buy |
| 2013-03-06 | Eingeleitet | Ascendiant Capital Markets | Strong Buy |
| 2008-01-03 | Eingeleitet | Dawson James | Speculative Buy |
Alle ansehen
Novabay Pharmaceuticals Inc Aktie (NBY) Neueste Nachrichten
StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World
NovaBay fails to gain shareholder approval for dissolution - MSN
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com - Defense World
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Press Release Distribution & PR Platform - ACCESS Newswire
NovaBay Pharmaceuticals approves liquidation plan By Investing.com - Investing.com Canada
NovaBay Pharmaceuticals approves liquidation plan - Investing.com
Poplar Point Capital Partners acquires $39,503 in NovaBay shares - Investing.com Australia
Poplar Point Capital Partners increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com South Africa
Poplar Point Capital increases stake in NovaBay Pharmaceuticals - Investing.com Australia
Massive Stock Acquisition: Poplar Point Capital Partners Bets Big on NovaBay Pharma! - TipRanks
Poplar Point Capital Partners acquires $29,857 in NovaBay shares - Investing.com Australia
Poplar Point Capital increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com India
Poplar Point Capital Partners acquires $39,503 in NovaBay shares By Investing.com - Investing.com India
Poplar Point Capital Partners acquires $29,857 in NovaBay shares By Investing.com - Investing.com Canada
Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions - Investing.com
Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions By Investing.com - Investing.com UK
NovaBay Pharmaceuticals sees $67,700 stock acquisition by Poplar Point Capital - Investing.com India
NovaBay Pharmaceuticals Inc. (NBY) reports earnings - qz.com
NovaBay Pharmaceuticals Delays Yearly Report Filing - TipRanks
Revolutionizing Healing: Trends in the Advanced Wound Care Market with NovaBay, Healthy.io - openPR.com
Blepharitis Treatment Market Future Business Opportunities - openPR.com
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Sees Significant Decrease in Short Interest - Defense World
NovaBay Pharmaceuticals (NBY) Projected to Post Quarterly Earnings on Tuesday - Defense World
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Share Price Passes Above 50-Day Moving Average – Time to Sell? - Defense World
NovaBay reaches settlements over disputed warrants By Investing.com - Investing.com Australia
NovaBay reaches settlements over disputed warrants - Investing.com India
NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Novabay Pharmaceuticals Engages Financial Advisor Should Stockholders Fail To Approve Dissolution Proposal - Marketscreener.com
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders - Business Wire
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Update - Defense World
StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World
Investor Network: NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
NovaBay's Avenova Highlighted in National Dry Eye Awareness Month - ACCESS Newswire
NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World
NovaBay extends CEO's contract through 2025 - MSN
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell? - Armenian Reporter
NovaBay fails to gain shareholder approval for dissolution By Investing.com - Investing.com Canada
Finanzdaten der Novabay Pharmaceuticals Inc-Aktie (NBY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novabay Pharmaceuticals Inc-Aktie (NBY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Apr 04 '25 |
Buy |
0.52 |
4,538 |
2,367 |
1,020,000 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Apr 02 '25 |
Buy |
0.58 |
917 |
532 |
992,486 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Apr 08 '25 |
Buy |
0.47 |
300 |
140 |
1,020,300 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 28 '25 |
Buy |
0.61 |
49,400 |
30,253 |
950,000 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 31 '25 |
Buy |
0.59 |
21,654 |
12,776 |
971,654 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 27 '25 |
Buy |
0.61 |
19,104 |
11,745 |
900,600 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Apr 01 '25 |
Buy |
0.58 |
19,915 |
11,650 |
991,569 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 26 '25 |
Buy |
0.61 |
13,292 |
8,095 |
881,496 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 25 '25 |
Buy |
0.61 |
22,635 |
13,807 |
868,204 |
| POPLAR POINT CAPITAL PARTNERS | 10% Owner |
Mar 18 '25 |
Buy |
0.63 |
14,000 |
8,820 |
832,277 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):